OHARA Pharmaceutical Co.,Ltd.


Locus

HOME into Business Unit at Ohara Pharmaceutical into Generic drugs business

Business Unit at Ohara Pharmaceutical

Generic drugs business

With the growing trends of a low birthrate and an aging society, it is now vital for Japan to establish a sustainable medical system to deal with these issues.

In order to maintain the national health insurance system and counter spiraling health care costs, there will be an increasing need for the wider utilization of generic drugs. We will put even more effort into meeting these societal demands.

High-quality pharmaceutical ingredients create high-quality pharmaceutical products.

In current pharmaceutical manufacture, pharmaceutical ingredients and their quality are becoming increasingly important.
Active pharmaceutical ingredients (API), is the term used globally to indicate the active ingredients of drugs.

The quality standards for generic drugs in Japan are said to be the most strict in the world.
In order to meet the exacting standards of the dissolution tests in particular, it is important to ensure a stable supply of pharmaceutical ingredients with consideration given not only to the chemical quality of the pharmaceutical ingredients but also to their physical properties.
For commodity API, which can be procured worldwide, we conduct optimized procurement based on a global network comprising three companies working together in a strategic capital alliance. Quality, cost and stability in supply are major considerations. In addition, specialty API, which require unique handling in Japan, are produced by the company API plant in Japan.

Ohara Pharmaceutical's network
  • Itochu Chemical Frontier Corporation
  • Inabata & Co., Ltd.
    • FRANCE - Pharmasynthese
  • CBC Co., Ltd.
    • ITALY - Procos

For example, the API which require unique handling in Japan include the following:
API with process patent in Japan, substance listed in the Japanese Pharmacopoeia with different specifications with USP/EP, API for which the specification of particle size at the API stage is important in order to adjust the dissolution testing for the preparation (such as poorly soluble drugs).

We are committed to maintaining the foundation of pharmaceutical development, namely, the procurement of high-quality material drugs to meet the high standards required of Japanese generic drugs, in order to deliver top quality generic drugs.